Martina Antoniolli

Martina Antoniolli

Auto-generated profile, based on publicly available information

Martina Antoniolli

Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development (pRED), Penzberg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
MMMichael Mentz
Michael Mentz
WKWilliam Keay
William Keay
CSCarolin Dorothea Strobl
Carolin Dorothea Strobl
MAMartina Antoniolli
Martina Antoniolli
LALouisa Adolph
Louisa Adolph
OWOliver Weigert
Oliver Weigert
The variable clinical course of follicular lymphoma (FL) is determined by the molecular heterogeneity of tumor cells and complex interactions within the tumor microenvironment (TME). IL-4 producing follicular helper T cells (TFH) are critical components of the FL TME. Binding of IL-4 to IL-4R on FL cells activates JAK/STAT signaling. We identified STAT6 mutations (STAT6MUT) in 13% of FL (N = 33/258), all clustered within the DNA binding domain. Gene expression data and immunohistochemistry showed upregulation of IL-4/STAT6 target genes in STAT6MUT FL, including CCL17, CCL22, and FCER2 (CD23). Functionally, STAT6MUT was gain-of-function by serial replating phenotype in pre-B CFU assays. Expression of STAT6MUT enhanced IL-4 induced FCER2/CD23, CCL17 and CCL22 expression and was associated with nuclear accumulation of pSTAT6. RNA sequencing identified PARP14 -a transcriptional switch and co-activator of STAT6- among the top differentially upregulated genes in IL-4 stimulated STAT6MUT lymphoma cells and in STAT6MUT primary FL cells. Quantitative chromatin immunoprecipitation (qChIP) demonstrated binding of STAT6MUT but not STAT6WT to the PARP14 promotor. Reporter assays showed increased IL-4 induced transactivation activity of STAT6MUT at the PARP14 promotor, suggesting a self-reinforcing regulatory circuit. Knock-down of PARP14 or PARP-inhibition abrogated the STAT6MUT gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6MUT FL.

23 January 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
MAMartina Antoniolli
Martina Antoniolli
MSMaria Solovey
Maria Solovey
JHJohannes Adrian Hildebrand
Johannes Adrian Hildebrand
TFTabea Freyholdt
Tabea Freyholdt
CSCarolin Dorothea Strobl
Carolin Dorothea Strobl
OWOliver Weigert
Oliver Weigert
The cell death receptor FAS and its ligand (FASLG) play crucial roles in the selection of B cells during the germinal center (GC) reaction. Failure to eliminate potentially harmful B cells via FAS can lead to lymphoproliferation and the development of B cell malignancies. The classic form of follicular lymphoma (FL) is a prototypic GC-derived B cell malignancy, characterized by the t(14;18)(q32;q21)IGH::BCL2 translocation and overexpression of antiapoptotic BCL2. Additional alterations were shown to be clinically relevant, including mutations in ARID1A. ARID1A is part of the SWI/SNF nucleosome remodeling complex that regulates DNA accessibility (“openness”). However, the mechanism how ARID1A mutations contribute to FL pathogenesis remains unclear. We analyzed 151 FL biopsies of patients with advanced-stage disease at initial diagnosis and found that ARID1A mutations were recurrent and mainly disruptive, with an overall frequency of 18%. Additionally, we observed that ARID1A mutant FL showed significantly lower FAS protein expression in the FL tumor cell population. Functional experiments in BCL2-translocated lymphoma cells demonstrated that ARID1A is directly involved in the regulation of FAS, and ARID1A loss leads to decreased FAS protein and gene expression. However, ARID1A loss did not affect FAS promotor openness. Instead, we identified and experimentally validated a previously unknown co-transcriptional complex consisting of RUNX3 and ETS1 that regulates FAS expression, and ARID1A loss leads to reduced RUNX3 promotor openness and gene expression. The reduced FAS levels induced by ARID1A loss rendered lymphoma cells resistant to both soluble and T cell membrane-anchored FASLG-induced apoptosis, and significantly diminished CAR T cell killing in functional experiments. In summary, we have identified a functionally and clinically relevant mechanism how FL cells can escape FAS-dependent immune surveillance, which may also impact the efficacy of T cell-based therapies, including CAR T cells.

9 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MAMartina Antoniolli
Martina Antoniolli
LSLlucia Albertí Servera
Llucia Albertí Servera
KPKerstin Paetzold
Kerstin Paetzold
SSStephan Schmeing
Stephan Schmeing
CYCarmen Yong
Carmen Yong
SDSteffen Dettling
Steffen Dettling
Background: Single-cell RNA sequencing (scRNA-seq) has become essential for understanding disease biology, yet its application in clinical trials is often limited by logistical challenges associated with the handling of biospecimens. Newly developed protocols aim to address these limitations by enabling profiling of fixed tissue. These new solutions need to be benchmarked against well-established protocols to assess their performance and suitability for clinical research. Results: We systematically compared different scRNA-seq protocols in a set of samples commonly analysed in clinical trials. The 10X Genomics GEM-X Flex Gene Expression assay (GEM-X Flex), in combination with the “chop-fix” preprocessing protocol, demonstrated superior performance to the standard GEM-X Universal Gene Expression solution when applied to both primary tumor tissue fragments and FFPE blocks. Moreover, the quality of the data obtained from GEM-X Flex applied to FFPE blocks outperformed that of single-nuclei RNA sequencing (snRNA-seq) from frozen biopsies, more robustly capturing the biological signals associated with the mechanism of action of a drug evaluated in an internal clinical trial. Conclusions: GEM-X Flex generates reliable, comprehensive transcriptomic data from both fixed tissue and clinical biopsies. By overcoming some of the limitations of fresh and frozen tissue analysis, this protocol offers a robust solution for the broad implementation of scRNA-seq in clinical trials.